menu
    • menu

    Company profile for Mirum Pharmaceuticals

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of rare liver diseases. We are advancing our lead candidate, maralixibat for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Mirum PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    950 Tower Lane, Suite 1050 Foster City, CA 94404
    Telephone
    Telephone
    650-667-4085
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://mirumpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/mirum-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/mirumpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mirum Pharma Secures More Private Funding From TCGX
    Mirum Pharma Secures More Private Funding From TCGX

    19 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-19/mirum-pharmaceuticals-announces-additional-private-placement-financing-with-tcgx

    PHARMIWEB
    19 Dec 2025
    Share Share
    Mirum Pharma Issues Inducement Grants Under Nasdaq Rule
    Mirum Pharma Issues Inducement Grants Under Nasdaq Rule

    10 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251210609338/en/Mirum-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    10 Dec 2025
    Share Share
    Mirum Pharma Enters into Definitive Agreement to Acquire Bluejay
    Mirum Pharma Enters into Definitive Agreement to Acquire Bluejay

    08 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-08/mirum-pharmaceuticals-enters-into-definitive-agreement-to-acquire-bluejay-therapeutics-expanding-gl

    PHARMIWEB
    08 Dec 2025
    Share Share
    Mirum Pharma Enrolls First Patient In BLOOM Ph2 Study
    Mirum Pharma Enrolls First Patient In BLOOM Ph2 Study

    01 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251201663577/en/Mirum-Pharmaceuticals-Announces-First-Patient-Enrolled-in-the-BLOOM-Phase-2-Clinical-Study-Evaluating-MRM-3379-in-Fragile-X-Syndrome

    BUSINESSWIRE
    01 Dec 2025
    Share Share
    Mirum Pharma To Join Investor Conferences
    Mirum Pharma To Join Investor Conferences

    25 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125053736/en/Mirum-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences

    BUSINESSWIRE
    25 Nov 2025
    Share Share
    Mirum Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
    Mirum Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)

    10 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251110057596/en/Mirum-Pharmaceuticals-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESS WIRE
    10 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search